Purdue Targets Sandoz Over OxyContin Patents

Law360, New York (July 11, 2011, 1:12 PM EDT) -- Purdue Pharma LP on Thursday launched a patent suit against Sandoz Inc. in New York, making the generic-drug maker the latest target of Purdue's efforts to protect the blockbuster pain medication OxyContin.

The lawsuit was launched in response to an abbreviated new drug application submitted by Sandoz to the U.S. Food and Drug Administration, seeking approval to produce generic oxycodone hydrochloride extended release tablets in 40-milligram and 80-milligram doses before the expiration of five patents owned or licensed by Purdue, according to the complaint.

Sandoz claims...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.